These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18220638)

  • 1. Therapeutic management strategies for type 2 diabetes.
    Ramesh C; Gopal V; Sembulingam K; Nappinnai M
    Curr Diabetes Rev; 2006 Aug; 2(3):339-42. PubMed ID: 18220638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications].
    Wolffenbuttel BH; Heine RJ
    Ned Tijdschr Geneeskd; 1999 Jun; 143(23):1197-201. PubMed ID: 10389533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
    ADVANCE Management Committee
    Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Normalization of blood pressure and lipids in patients with diabetes].
    Clemens A; Gallwitz B
    Med Klin (Munich); 2003 Jul; 98(7):368-76. PubMed ID: 12937902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes mellitus: an evolving therapeutic approach.
    McElduff A
    P N G Med J; 2001; 44(3-4):124-30. PubMed ID: 12422983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 8. Should we use intensive insulin therapy after oral agent failure in type II diabetes?
    Colwell JA
    Diabetes Care; 1996 Aug; 19(8):896-8. PubMed ID: 8842613
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction.
    Gerstein HC
    Diabetes Care; 2000 Jul; 23(7):882-3. PubMed ID: 10895833
    [No Abstract]   [Full Text] [Related]  

  • 10. Residual microvascular risk in diabetes: unmet needs and future directions.
    Fioretto P; Dodson PM; Ziegler D; Rosenson RS
    Nat Rev Endocrinol; 2010 Jan; 6(1):19-25. PubMed ID: 19859073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension in type 2 diabetes--targeting angiotensin.
    Drug Ther Bull; 2005 Jun; 43(6):41-5. PubMed ID: 15966556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiosyncratic pancreatitis associated with perindopril.
    Famularo G; Minisola G; Nicotra GC; De Simone C
    JOP; 2005 Nov; 6(6):605-7. PubMed ID: 16286714
    [No Abstract]   [Full Text] [Related]  

  • 13. [Angiotensin converting enzyme inhibitors in the treatment of diabetes].
    Smahelová A
    Vnitr Lek; 2003 Dec; 49(12):948-51. PubMed ID: 15040161
    [No Abstract]   [Full Text] [Related]  

  • 14. Economics of type 2 diabetes prevention.
    Kissimova-Skarbek K
    Przegl Lek; 2006; 63 Suppl 4():9-11. PubMed ID: 16967708
    [No Abstract]   [Full Text] [Related]  

  • 15. New frontiers in the management of type 2 diabetes.
    Mudaliar S
    Indian J Med Res; 2007 Mar; 125(3):275-96. PubMed ID: 17496356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus.
    Nosadini R; Abaterusso C; Dalla Vestra M; Bortoloso E; Saller A; Bruseghin M; Sfriso A; Trevisan M
    Nephrol Dial Transplant; 1998; 13 Suppl 8():44-8. PubMed ID: 9870425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.
    Pahor M; Psaty BM; Alderman MH; Applegate WB; Williamson JD; Furberg CD
    Diabetes Care; 2000 Jul; 23(7):888-92. PubMed ID: 10895836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.
    Vijan S; Hayward RA
    Ann Intern Med; 2003 Apr; 138(7):593-602. PubMed ID: 12667032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.